MedTrace Logo

Saxagliptin Triple Oral Therapy

NCT01128153 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2012-08-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.

Conditions

Interventions

DRUG

Saxagliptin

5 mg tablet once daily for 24 weeks to be taken orally

DRUG

Placebo

tablet once daily for 24 weeks to be taken orally

Sponsors & Collaborators

Principal Investigators

  • Jayanti Visvanthan, MD · AstraZeneca

  • Simon Fisher, MD · AstraZeneca

  • Vinod Mattoo, MD · Bristol-Myers Squibb

  • Robert Moses, MBBS · Sydney Diabetes Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Australia
  • Canada
  • India
  • South Korea
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128153 on ClinicalTrials.gov